Ed Shenkan

Ed Shenkan

Ed Shenkan is an experienced corporate director, healthcare financial analyst, strategic consultant, and pharmaceuticals operator with a deep knowledge of public and private healthcare companies.1 He currently serves as the CEO, Strategic Advisor and Consultant at Shenkan Advisors, a consulting firm he founded in May 2009.13

Key Highlights

• Has FDA experience and an extensive network in the investment community1
• Provides input on strategic planning, financial modeling, capital raising, product positioning, M&A opportunities, and exit strategies for boards1
• Chairs public company Audit Committees and satisfies SEC requirements1
• Assists healthcare company boards, management teams, and investors with strategic decisions and due diligence on acquisitions and investments using proprietary market research13
• Advises institutional investors and companies on investment decisions, market assessments, and company valuations3
• Surveys and interviews several thousand physicians, medical providers, administrators, and payors annually to incorporate qualitative and quantitative primary research into financial models and analysis3
• Helps private equity investors and companies screen M&A, perform due diligence, and evaluate white spaces3
• Develops business strategies to create long-term value and roadmaps for future bolt-on acquisitions3
• Analyzes capital allocation decisions for boards and management teams3
• Assists companies in developing strategic market assessments for existing and new markets3

Recent Roles

• Associate Director FDA CDRH, General Manager Total Product Life Cycle Advisors Program (TAP) (October 2022 - November 2023)12
• Launched the TAP program and its consulting practice to help breakthrough products obtain regulatory approval and market access1

Education

• MBA, Harvard Business School
• BA, Dartmouth College